Survival of patients with malignancy over the last 30 years has continually improved due to advancements in aggressive chemotherapeutic regimens as well as supportive measures toward treatment and prevention of infection.^[@bib1],[@bib2]^ Even though cancer remains a significant cause of mortality in children, 5-year survival for childhood cancers, including hematologic malignancies and solid tumors, is greater than 80%. In these children, critical illness occurs either as a result of their malignancies and/or complications from treatment. Given improvements in survival, a more aggressive approach to the management of these complications in pediatric patients with malignancies has been encouraged, which has enlightened the medical community to the use of extracorporeal life support (ECLS) in this complex population. Evidence of this new approach was reported in 2009 by Gow et al.^[@bib3]^ when a survey of ECLS centers regarding utilization of ECLS for patients with malignancy found that 95% of respondent ECLS centers felt that malignancy was not a contraindication to ECLS. This is further supported by the Extracorporeal Life Support Organization (ELSO) registry, which documents that, since 1997, the use of ECLS, including extracorporeal membrane oxygenation (ECMO) for pediatric cancer patients has been steadily rising.

Up until 2007, pediatric patients with malignancy comprised 0.5% of all ECLS patients. Limitation in the use of ECLS for patients with cancer was most likely influenced by cancer-related mortality as well as the ideology of ECLS being a support modality offered only to acutely ill "healthy" patients. Since 2009, a number of reports describing ECLS use for patients with malignancy have been published, implying that its use is increasing in this population most likely due to noted improved oncologic survival compounded by more widespread ECLS use in complex patient populations. Utilization of this support modality in pediatric malignancy, although still low compared with other populations, is increasing. In 2008--2012, the ELSO registry documented 178 patients with malignancy who received ECLS, which equates to 1% and a doubling of utilization compared with that reported previously. Although there is still a small portion of ECLS patients, education regarding the use of this modality of support for patients with malignancy will likely lead to further increases in utilization.^[@bib4],[@bib5]^
